Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-10-09
2002-09-24
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S519000
Reexamination Certificate
active
06455570
ABSTRACT:
SUMMARY OF THE INVENTION
Most tissues exist in a highly regulated dynamic equilibrium wherein new tissue is formed and existing tissue is degraded and eliminated. The degradation of the extracellular matrix (ECM), including connective tissue and basement membranes, is effected by the metalloproteinases which are released from connective tissue and invading inflammatory cells. There are at least four distinct groups of the more than 20 matrix metalloproteinases (MMP) which have been identified (Birkedal-Hansen, H.
J. Oral Pathol.
1988 17:445; Birkedal-Hansen, H.
Curr. Opin. Cell Biol.
1995 7:728; Emonard, H.; Grimaud, J. A.
Cell. Mol. Biol.
1990 36:131; Murphy, G.; Docherty, A. J. P.
Am. J Respir. Cell Mol. Biol.
1992 7:120; Baramova, E.; Foidart, J.
Cell Biol. Int.
1995 19:239; Borkakoti, N.
Prog. Biophys. Mol. Biol.
1998 70:73; Johnson, L. L., Dyer, R., Hupe, D. J.
Curr. Opin. Chem.Biol.
1998 2:466; Shapiro, S. D.; Senior, R. M.
Am. J. Respir. Cell Mol. Biol.
1999 20:1100): the collagenases (interstitial collagenase, MMP-1; PMN collagenase, MMP-8, collagenase-3, MMP- 13), the gelatinases (gelatinase A, MMP-2, 72 kDa-gelatinase, Type IV collagenase; gelatinase B, MMP-9, 92 kDa-gelatinase, Type IV collagenase) the stromelysins (proteoglycanase, MMP-3, stromelysin-1, transin; stromelysin-2, MMP-10; stromelysin 3, MMP-11) and the membrane type matrix metalloproteinases (MT-1, MMP-14; MT-2, MMP-15; MT-3, MMP-16 and MT-4, MMP-17). Excessive unregulated activity of these enzymes can result in undesirable tissue destruction and their activity is regulated at the transcription level, by controlled activation of the latent proenzyme and, after translation, by intracellular specific inhibitory factors such as TIMP (“Tissue Inhibitors of MetalloProteinase”) or by more general proteinase inhibitors such as &agr;2-macroglobulins.
Inhibitors of MMPs also have been found to inhibit the release of the pleiotropic proinflammatory cytokine, tumor necrosis factor alpha which has be associated with the pathogenesis of numerous inflammatory, autoimmune, and neoplastic diseases. The protease, TNF&agr;-Converting Enzyme (TACE), catalyzes the release of TNF&agr; from a membrane bound precursor protein.
The MMPs are a family of related proteolytic enzymes. They are zinc-binding metalloproteases linked by structural homology and by proteolytic activity against various components of the ECM while exhibiting divergent substrate specificity and activities. Calcium is generally required for maximum activity. They are distinguished from other metalloproteases by their susceptibility to activation of the zymogen by thiol-modifying reagents, mercurial compounds, N-ethylmaleimide and oxidized glutathione, by their inhibition by a group of endogenous substances known collectively as TIMPs, and by the presence of a consensus sequence in their propeptide forms. (H. Nagase, “Matrix Metalloproteinases,” chapter 7, ppl53-204 in
Zinc Metalloproteases in Health and Disease
“N. M. Hooper (ed.), Taylor and Francis, London (1996)).
Many pathological conditions are associated with the rapid unregulated breakdown of extracellular matrix tissue by MMPs. Some of these conditions include rheumatoid arthritis, osteoarthritis, septic arthritis, corneal, epidermal or gastric ulceration; periodontal disease, proteinuria, coronary thrombosis associated with atherosclerotic plaque rupture and bone disease. The process of tumor metastasis and angiogenesis also appears to be dependent on MMP activity. Since the cycle of tissue damage and response is associated with a worsening of the disease state, limiting MMP-induce tissue damage due to elevated levels of the proteinases with specific inhibitors of these proteases is a generally useful therapeutic approach to many of these debilitating diseases (for a general review see R C Wahl, et al.
Ann. Rep, Med. Chem.
1990 25:175-184; Zask, A.; Levin, J. I.; Killar, L. M., Skotnicki, J. S.
Curr. Pharm. Des.
1996, 2, 624).
It is an object of the present invention to provide novel selective, small molecule inhibitors of matrix metalloproteinases which can be used to modulate the progression of the underlying diseases and to treat diseases associated with excessive MMP-induced tissue damage.
REFERENCES:
patent: 5489692 (1996-02-01), Hirschmann et al.
patent: 5514814 (1996-05-01), Hirschmann et al.
patent: 5770732 (1998-06-01), Hirschmann et al.
Smith AB 3rd, Nittoli T, Sprengeler PA, Duann JJ, Liu RQ, Hirshmann RF. “Design, synthesis, and evaluation of a pyrrolinone- based matrix metalloprotease inhibitor”. Nov. 30, 2000, Organic Letters, 2(24): 3809-12.*
Birkedal-Hansen, H., Curr. Opin. Cell Biol., 1995, 7:728.
Johnson, L.L., Dyer, R., Hupe, D.J., Curr. Opin. Chem. Biol., 1998, 2:466.
Johnson, W.H., et al., J. Enzyme Inhib., 1987 2:1.
Borkakoti, N., et al., Struct. Biol., 1994, 1(2):106-110.
Sudoh, M. et al., Pharm. Res., 1998, 15(5) 719-25.
R. Babine And S. Bender, Chem. Rev., 1997, 97:1359.
Whittaker, M. et al., Chem. Rev., 1999, 99:2735-76.
Smith, A. B., III, et al., Org. Lett., 2000, 2(24):2809-12.
Smith, A. B., III, et al., Bioorg. Med. Chem., 1999, 7:9-22.
Smith, A. B., III, et al., Tetrahedron Lett., 1997, 38(22):3809-3812.
Smith, A. B., III, et al., Tetrahedron Lett., 1993, 34(1):63-66.
Smith, A. B., III, et al., Biopolymers (Peptide Science), 1995, 37:29-53.
Smith, A. B., III, et al., J. Am. Chem. Soc., 1992, 114, 10672-64.
Smith, A. B., III, et al., J. Med. Chem., 1994, 37, 215-18.
Smith, A. B., III, et al., Bioorg. Med. Chem., 1996, 4(7):1021-24.
Smith, A. B., III, et al., J. Am. Chem. Soc., 1994, 116,9947.
Smith, A. B., III., et al., J. Am. Chem. Soc., 1998, 120, 12704.
Smith, A. B., III, et al., J. Am. Chem. Soc., 1999, 121:9286-98.
Smith, A. B., III, et al., J. Med. Chem., 1997, 40, 2440-44.
Smith, A. B., III, et al., J. Am. Chem. Soc., 1995, 117, 11113-23.
Hirschmann, R., et al., In New Perspectives in Drug Design: Dean, P.M., Jolles, G., Newton, C.G., Eds.; Academic: London, 1995, pp 1-14.
Smith, A. B., III, et al., Org Lett, 2000, 2(4):2037.
Smith, A. B., III et al. Org Lett 2000 2(4):2041.
Hirschmann Ralph F.
Nittoli Thomas
Smith, III Amos B.
Sprengeler Paul
Ahmed Sameena
Mathews, Collins Shepherd & McKay, P.A.
McKane Joseph K.
The Trustees of the University of Pennsylvania
LandOfFree
Polypyrrolinone based inhibitors of matrix metalloproteases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypyrrolinone based inhibitors of matrix metalloproteases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypyrrolinone based inhibitors of matrix metalloproteases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2861602